Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-21 23:39:37 Source:businessViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous:These hilarious notices will make you do a double take
Next:Padres second baseman Xander Bogaerts leaves game against Braves with shoulder injury
You may also like
- Sophie Morgan suddenly quits ITV show Loose Women as she reveals plans for emigration
- Outage hits Apple services, including App Store and Apple TV+
- Electoral Commission probes concerns about voting at Te Pāti Māori candidate's marae
- David Cameron's Falklands visit prompts playful dig from Buenos Aires
- Arrest Lord Mountbatten's self
- RNZ's pips are changing
- Roads crack, flights grounded as rare earthquake hits US east coast
- Attendance action plan includes daily data, traffic light system
- A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it